Literature DB >> 29620925

Sexualized Drug Use (Chemsex) Is Associated with High-Risk Sexual Behaviors and Sexually Transmitted Infections in HIV-Positive Men Who Have Sex with Men: Data from the U-SEX GESIDA 9416 Study.

Alicia González-Baeza1, Helen Dolengevich-Segal2, Ignacio Pérez-Valero1, Alfonso Cabello3, María Jesús Téllez4, José Sanz5, Leire Pérez-Latorre6, José Ignacio Bernardino1, Jesús Troya7, Sara De La Fuente8, Otilia Bisbal9, Ignacio Santos10, Sari Arponen11, Víctor Hontañon1, José Luis Casado12, Pablo Ryan7,13.   

Abstract

The magnitude of sexualized drug use (SDU), also known as chemsex, and its association with sexually transmitted infections (STI) has not been systematically explored in HIV-positive patients. This study aimed to calculate the prevalence of SDU and associated factors in a sample of HIV-positive men who have sex with men (MSM) in Spain. We calculated the frequency of SDU in a sample of HIV-positive MSM who responded to an anonymous online survey on sexual behavior and recreational drug use. We also analyzed differences between those who responded and those who did not (data taken from the physician's registry). The association between SDU, sexual risk behaviors, and STI was evaluated using a univariate and a multivariate analysis. Data were collected and managed using Research Electronic Data Capture (REDCap). The survey was completed by 742 HIV-positive MSM, of whom 60% had had unprotected anal intercourse (UAI), 62% had been diagnosed with a STI, and 216 (29.1%) reported recent SDU (slamsex in 16% of cases). In the multivariate analysis, patients who engaged in SDU were more likely to have had high-risk sexual behaviors and a diagnosis of STI than participants who did not engage in SDU. A diagnosis of hepatitis C was independently associated with slamsex (5.2 [95% confidence interval (CI), 2.06-13.13]; p < 0.001), chemsex (2.51 [95% CI, 1.28-4.91]; p = 0.007), and UAI (1.82 [95% CI, 0.90-3.70]; p = 0.094). The magnitude of SDU or chemsex in our sample is relatively high. We found a clear association between SDU, high-risk sexual behaviors, and STI including hepatitis C.

Entities:  

Keywords:  MSM; chemsex; high-risk sexual behaviors; human immunodeficiency virus; sexualized drug use; sexually transmitted infections

Mesh:

Year:  2018        PMID: 29620925     DOI: 10.1089/apc.2017.0263

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  22 in total

1.  Ecological and Syndemic Predictors of Drug Use During Sex and Transactional Sex among U.S. Black Men Who Have Sex with Men: A Secondary Data Analysis from the HPTN 061 Study.

Authors:  Natalie M Leblanc; Hugh F Crean; Typhanye P Dyer; Chen Zhang; Rodman Turpin; Nanhua Zhang; Martez D R Smith; James McMahon; LaRon Nelson
Journal:  Arch Sex Behav       Date:  2021-04-26

2.  Empirical Evaluation of Rainbow Reflections: A Comic Book Anthology on Body Image for Queer Men.

Authors:  Stéphanie E M Gauvin; Phillip Joy; Brittany L Dunn; Matthew Lee; Rachel E Williamson
Journal:  Arch Sex Behav       Date:  2021-01-04

3.  Risk factors for HCV transmission in HIV-positive men who have sex with men in México.

Authors:  José Antonio Mata-Marín; Armando Abraham de Pablos-Leal; Stefan Mauss; Carla Ileana Arroyo-Anduiza; Mara Soraya Rodríguez-Evaristo; Luis Antonio Uribe-Noguéz; María de Los Ángeles Berrospe-Silva; Juan Carlos Lara-Castañeda; Edgar Pérez-Barragán; Jesús Gaytán-Martínez
Journal:  PLoS One       Date:  2022-07-15       Impact factor: 3.752

4.  Seroprevalence of Hepatitis B Virus, Hepatitis C Virus, Syphilis and Associated Factors Among Female Sex Workers in Gondar Town, Northwest Ethiopia.

Authors:  Mitikie Wondmagegn; Yitayih Wondimeneh; Alem Getaneh; Getnet Ayalew
Journal:  Infect Drug Resist       Date:  2022-10-14       Impact factor: 4.177

5.  Association of Sexualized Drug Use Patterns with HIV/STI Transmission Risk in an Internet Sample of Men Who Have Sex with Men from Seven European Countries.

Authors:  Juan-Miguel Guerras; Juan Hoyos Miller; Cristina Agustí; Sophocles Chanos; François Pichon; Matthias Kuske; Bojan Cigan; Ricardo Fuertes; Roxana Stefanescu; Lieselot Ooms; Jordi Casabona; Luis de la Fuente; María-José Belza
Journal:  Arch Sex Behav       Date:  2020-09-02

6.  Syndemic latent transition analysis in the HPTN 061 cohort: Prospective interactions between trauma, mental health, social support, and substance use.

Authors:  Rodman E Turpin; Typhanye V Dyer; Derek T Dangerfield; Hongjie Liu; Kenneth H Mayer
Journal:  Drug Alcohol Depend       Date:  2020-06-26       Impact factor: 4.492

7.  Psychological and Interpersonal Factors Associated with Sexualized Drug Use Among Men Who Have Sex with Men: A Mixed-Methods Systematic Review.

Authors:  David Lafortune; Martin Blais; Geneviève Miller; Laurence Dion; Frédérick Lalonde; Luc Dargis
Journal:  Arch Sex Behav       Date:  2020-10-27

8.  Prevalence and patterns of illicit drug use in people living with HIV in Spain: A cross-sectional study.

Authors:  Maria Jose Fuster-RuizdeApodaca; Vanessa Castro-Granell; Noé Garin; Ana Laguía; Ángeles Jaén; Carlos Iniesta; Santiago Cenoz; María José Galindo
Journal:  PLoS One       Date:  2019-06-17       Impact factor: 3.240

9.  Sociodemographic changes and trends in the rates of new perinatal HIV diagnoses and transmission in Spain from 1997 to 2015.

Authors:  Santiago Jiménez de Ory; José Tomas Ramos; Claudia Fortuny; María Isabel González-Tomé; Maria José Mellado; David Moreno; César Gavilán; Ana Isabel Menasalvas; Ana Isabel Piqueras; M Antoinette Frick; Maria Angeles Muñoz-Fernández; Maria Luisa Navarro
Journal:  PLoS One       Date:  2019-10-24       Impact factor: 3.240

10.  Sex, Drugs, and Impulse Regulation: A Perspective on Reducing Transmission Risk Behavior and Improving Mental Health Among MSM Living With HIV.

Authors:  Rachel M Arends; Thom J van den Heuvel; Eline G J Foeken-Verwoert; Karin J T Grintjes; Hans J G Keizer; Aart H Schene; André J A M van der Ven; Arnt F A Schellekens
Journal:  Front Psychol       Date:  2020-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.